Premium
A Peptidomimetic HIV‐Entry Inhibitor Directed against the CD4 Binding Site of the Viral Glycoprotein gp120
Author(s) -
Neffe Axel T.,
Meyer Bernd
Publication year - 2004
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.200353271
Subject(s) - peptidomimetic , glycoprotein , peptide , chemistry , human immunodeficiency virus (hiv) , entry inhibitor , binding site , stereochemistry , virology , biochemistry , biology , viral entry , virus , viral replication
Barring infection : A new CD4‐binding peptidomimetic (see ball‐and‐stick structure; CD4 is shown in green) has been designed and synthesized as an entry inhibitor of the HIV virus. The binding affinity of the peptidomimetic for CD4 is 40 μ M , which is 150‐fold better than that of the lead peptide NMWQKVGTPL. The mimetic also has a lower molecular weight and a higher proteolytic stability than the lead peptide.